BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 17130299)

  • 1. Deregulated Syk inhibits differentiation and induces growth factor-independent proliferation of pre-B cells.
    Wossning T; Herzog S; Köhler F; Meixlsperger S; Kulathu Y; Mittler G; Abe A; Fuchs U; Borkhardt A; Jumaa H
    J Exp Med; 2006 Dec; 203(13):2829-40. PubMed ID: 17130299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis.
    Coffey G; DeGuzman F; Inagaki M; Pak Y; Delaney SM; Ives D; Betz A; Jia ZJ; Pandey A; Baker D; Hollenbach SJ; Phillips DR; Sinha U
    J Pharmacol Exp Ther; 2012 Feb; 340(2):350-9. PubMed ID: 22040680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells.
    Gobessi S; Laurenti L; Longo PG; Carsetti L; Berno V; Sica S; Leone G; Efremov DG
    Leukemia; 2009 Apr; 23(4):686-97. PubMed ID: 19092849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia.
    Buchner M; Baer C; Prinz G; Dierks C; Burger M; Zenz T; Stilgenbauer S; Jumaa H; Veelken H; Zirlik K
    Blood; 2010 Jun; 115(22):4497-506. PubMed ID: 20335218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation.
    Braselmann S; Taylor V; Zhao H; Wang S; Sylvain C; Baluom M; Qu K; Herlaar E; Lau A; Young C; Wong BR; Lovell S; Sun T; Park G; Argade A; Jurcevic S; Pine P; Singh R; Grossbard EB; Payan DG; Masuda ES
    J Pharmacol Exp Ther; 2006 Dec; 319(3):998-1008. PubMed ID: 16946104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can treating the SYK cell cure leukemia?
    Downing JR
    Cancer Cell; 2009 Oct; 16(4):270-1. PubMed ID: 19800569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCdelta and proteasome-dependent regulation of Mcl-1 expression.
    Baudot AD; Jeandel PY; Mouska X; Maurer U; Tartare-Deckert S; Raynaud SD; Cassuto JP; Ticchioni M; Deckert M
    Oncogene; 2009 Sep; 28(37):3261-73. PubMed ID: 19581935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myc enhances B-cell receptor signaling in precancerous B cells and confers resistance to Btk inhibition.
    Moyo TK; Wilson CS; Moore DJ; Eischen CM
    Oncogene; 2017 Aug; 36(32):4653-4661. PubMed ID: 28368423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic prospect of Syk inhibitors.
    Ruzza P; Biondi B; Calderan A
    Expert Opin Ther Pat; 2009 Oct; 19(10):1361-76. PubMed ID: 19670961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406.
    Quiroga MP; Balakrishnan K; Kurtova AV; Sivina M; Keating MJ; Wierda WG; Gandhi V; Burger JA
    Blood; 2009 Jul; 114(5):1029-37. PubMed ID: 19491390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphorylation of the activation loop tyrosines is required for sustained Syk signaling and growth factor-independent B-cell proliferation.
    Carsetti L; Laurenti L; Gobessi S; Longo PG; Leone G; Efremov DG
    Cell Signal; 2009 Jul; 21(7):1187-94. PubMed ID: 19296913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative phosphoproteomics revealed interplay between Syk and Lyn in the resistance to nilotinib in chronic myeloid leukemia cells.
    Gioia R; Leroy C; Drullion C; Lagarde V; Etienne G; Dulucq S; Lippert E; Roche S; Mahon FX; Pasquet JM
    Blood; 2011 Aug; 118(8):2211-21. PubMed ID: 21730355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic potential of spleen tyrosine kinase inhibition for treating high-risk precursor B cell acute lymphoblastic leukemia.
    Perova T; Grandal I; Nutter LM; Papp E; Matei IR; Beyene J; Kowalski PE; Hitzler JK; Minden MD; Guidos CJ; Danska JS
    Sci Transl Med; 2014 May; 6(236):236ra62. PubMed ID: 24828076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abl family kinases regulate FcγR-mediated phagocytosis in murine macrophages.
    Greuber EK; Pendergast AM
    J Immunol; 2012 Dec; 189(11):5382-92. PubMed ID: 23100514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spleen tyrosine kinase (Syk) is a potent target for GvHD prevention at different cellular levels.
    Leonhardt F; Zirlik K; Buchner M; Prinz G; Hechinger AK; Gerlach UV; Fisch P; Schmitt-Gräff A; Reichardt W; Zeiser R
    Leukemia; 2012 Jul; 26(7):1617-29. PubMed ID: 22301676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The kinase Syk as an adaptor controlling sustained calcium signalling and B-cell development.
    Kulathu Y; Hobeika E; Turchinovich G; Reth M
    EMBO J; 2008 May; 27(9):1333-44. PubMed ID: 18369315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes.
    Cha HS; Boyle DL; Inoue T; Schoot R; Tak PP; Pine P; Firestein GS
    J Pharmacol Exp Ther; 2006 May; 317(2):571-8. PubMed ID: 16452391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spleen tyrosine kinase (Syk) inhibitor fostamatinib limits tissue damage and fibrosis in a bleomycin-induced scleroderma mouse model.
    Pamuk ON; Can G; Ayvaz S; Karaca T; Pamuk GE; Demirtas S; Tsokos GC
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S15-22. PubMed ID: 26148346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockade of Syk ameliorates the development of murine sclerodermatous chronic graft-versus-host disease.
    Le Huu D; Kimura H; Date M; Hamaguchi Y; Hasegawa M; Hau KT; Fujimoto M; Takehara K; Matsushita T
    J Dermatol Sci; 2014 Jun; 74(3):214-21. PubMed ID: 24679982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CIN85 is required for Cbl-mediated regulation of antigen receptor signaling in human B cells.
    Niiro H; Jabbarzadeh-Tabrizi S; Kikushige Y; Shima T; Noda K; Ota S; Tsuzuki H; Inoue Y; Arinobu Y; Iwasaki H; Shimoda S; Baba E; Tsukamoto H; Horiuchi T; Taniyama T; Akashi K
    Blood; 2012 Mar; 119(10):2263-73. PubMed ID: 22262777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.